CorMedix to Participate in Upcoming January Conferences

Rhea-AI Summary

CorMedix Inc. (Nasdaq: CRMD) announced participation in multiple upcoming investor conferences in January 2022. Key events include:

• LifeSci Partners – January 5-7
• H.C. Wainwright Bioconnect Virtual Conference – January 10-13
• Biotech Showcase Virtual Conference – January 10-12

CorMedix focuses on developing therapeutic products, notably DefenCath™, for preventing life-threatening infections related to central venous catheters in hemodialysis patients. The FDA has designated DefenCath as Fast Track and QIDP, offering extended marketing exclusivity upon NDA approval.

BERKELEY HEIGHTS, N.J., Jan. 04, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that CorMedix management will be participating in several upcoming investor conferences in January.

Investor Conference Details

LifeSci Partners – 11^th Annual Corporate Access Event
        Wednesday, January 5^th – Friday, January 7^th
        To register and submit one-on-one meeting requests, Click Here

H.C. Wainwright Bioconnect Virtual Conference
        Monday, January 10^th – Thursday, January 13^th
        To register for the conference, Click Here

Biotech Showcase Virtual Conference
        Monday, January 10^th – Wednesday, January 12^th
        To register and submit one-on-one meeting requests, Click Here

About CorMedix

CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company is focused on developing its lead product DefenCath™, a novel, antibacterial and antifungal solution designed to prevent costly and life-threatening bloodstream infections associated with the use of central venous catheters in patients undergoing chronic hemodialysis. DefenCath has been designated by FDA as Fast Track and as a Qualified Infectious Disease Product (QIDP), and the NDA received priority review in recognition of its potential to address an unmet medical need. QIDP provides for an additional five years of marketing exclusivity, which will be added to the five years granted to a New Chemical Entity upon approval of the NDA. CorMedix also committed to conducting a clinical study in pediatric patients using a central venous catheter for hemodialysis when the NDA is approved, which will add an additional six months of marketing exclusivity when the study is completed. The Company received a Complete Response Letter from FDA stating that the NDA could not be approved until satisfactory resolution of deficiencies at the contract manufacturing facility, including in-process controls for the filling operation. CorMedix also intends to develop DefenCath as a catheter lock solution for use in oncology and total parenteral nutrition patients. It is leveraging its taurolidine technology to develop a pipeline of antimicrobial medical devices, with programs in surgical sutures and meshes, and topical hydrogels. The Company is also working with top-tier researchers to develop taurolidine-based therapies for rare pediatric cancers. Neutrolin® is CE Marked and marketed in Europe and other territories as a medical device. For more information, visit: www.cormedix.com.

Investor Contact:
Dan Ferry
Managing Director
LifeSci Advisors
(617) 430-7576

FAQ

What investor conferences will CorMedix participate in January 2022?

CorMedix will participate in the LifeSci Partners Annual Corporate Access Event (January 5-7), H.C. Wainwright Bioconnect Virtual Conference (January 10-13), and Biotech Showcase Virtual Conference (January 10-12).

What is DefenCath and its significance for CorMedix?

DefenCath is CorMedix's lead product aimed at preventing bloodstream infections in patients undergoing chronic hemodialysis. It has received Fast Track designation and QIDP status from the FDA.

What exclusivity does DefenCath have after FDA approval?

DefenCath is eligible for an additional five years of marketing exclusivity due to its QIDP designation, on top of the five years granted to new chemical entities upon approval.

What was the FDA's response to CorMedix's NDA for DefenCath?

The FDA issued a Complete Response Letter indicating that the NDA could not be approved until deficiencies at the contract manufacturing facility are resolved.

What other areas is CorMedix exploring for DefenCath?

CorMedix plans to develop DefenCath as a catheter lock solution for oncology and total parenteral nutrition patients, leveraging its taurolidine technology.